RR Acute Myelogenous Leukemia/ HR Myelodysplasia

Phase 1 (ASH Data Presentation)

Exp Date

Dec 5-8, 2020

Amp Volatility Score

Catalyst Info & Data Links



  • ~13K MDS incidence per year in the U.S.

  • ~30% of MDS cases progress to AML

  • ~35.7K prevalence for AML 

  • ~18.8K Patients with new AML diagnoses 

  • (Source)


  • APTO-253 as a Small Molecular MYC Inhibitor: APTO-253 does not target directly the MYC protein, but rather binds directly and selectively to a regulatory motif in the promoter of the MYC oncogene and dramatically down-regulates expression of the MYC protein in tumor cells, leading to apoptotic cell death. Thus, APTO-253 may serve as a safe and effective MYC inhibitor for MYC-driven or MYC-dependent tumors that combines well with other anti-tumor agents.

Updated by HC

APTO, APTO-253, acute_myeloid_leukemia, myelodysplastic_syndrome, ASH, ASH2020

Prior Data (click to view full image)


Trial Design / Revenue (click to view full image)


Recent Posts

See What The Community Is Saying - Click To See Full Post

APTO EHA 2020 ...

APTO is presenting data at EHA 2020 for their BTK and FLT-3 inhibitor CG-806 at EHA. Get our take on the likely movement and our investment strategy going forward. CLICK HERE (Free sign-up required fo...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon